Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Medicine
- Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, bacillus difficilis.Am J Dis Child. 1935; 49: 390-402
- Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.N Engl J Med. 1978; 298: 531-534
- Clostridium difficile—more difficult than ever.N Engl J Med. 2008; 359: 1932-1940
- Clindamycin-associated colitis.Ann Intern Med. 1974; 81: 429-433
- American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection.Am J Gastroenterol. 2013; 108: 177-185
- Treating clostridium difficile infection with fecal microbiota transplantation.Clin Gastroenterol Hepatol. 2011; 9: 1044-1049
- Narrative review: the new epidemic of Clostridium difficile-associated enteric disease.Ann Intern Med. 2006; 145: 758-764
- Fidaxomicin: first-in-class macrocyclic antibiotic.Expert Rev Anti Infect Ther. 2011; 9: 767-777
- ‘Game changer’ antibiotic and others in works for superbug.Nat Med. 2011; 17: 10
- Public Workshop: Fecal Microbiota for Transplantation: Scientific and Regulatory Issues Center for Biologics, Evaluation, and Research for Biologics, Evaluation and Research (FDA) and the National Institute for Allergy and Infectious Diseasees (NIH).Food and Drug Administration, Bethesda, MD2013
- Guidelines for diagnosis, treatment, and prevention of clostridium difficle infections.Am J Gastroenterol. 2013; 108: 478-498
- Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent clostridium difficile infection.Am J Gastroenterol. 2012; 107: 1079-1087
- Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection.Gastroenterology. 2012; 142: 490-496
- Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.Am J Gastroenterol. 2013; 108: 500-508
- Fidaxomicin versus vancomycin for Clostridium difficle infection.N Engl J Med. 2011; 364: 422-431
- Fidaxomicin: new therapy for Clostridium difficile-associated diarrhea.Formulary. 2011; 46: 297-308
- Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent clostridium difficile infection.Clin Infect Dis. 2011; 53: 994-1002
- Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis.Surgery. 1958; 44: 854-859
- Fecal microbiota transplantation–an old therapy comes of age.N Engl J Med. 2013; 368: 474-475
- Fecal microbiota transplantation: techniques, applications, and issues.Gastroenterol Clin North Am. 2012; 41: 781-803
- Refractory clostridium difficile infection: untraditional treatment of antibiotic-induced colitis.Tidsskr Nor Laegeforen. 1991; 111: 1364-1365
- Functional interactions between the gut microbiota and host metabolism.Nature. 2012; 489: 242-249
UpToDate. Spatial organization of the intestinal microbiota in health and disease; 2013. Available at: http://www.uptodate.com/contents/spatial-organization-of-intestinal-microbiotia-in-health-and-disease. Accessed June 4, 2013.
- Commensal bacteria in the gut: learning who our friends are.Curr Opin Gastroenterol. 2004; 20: 565-571
- Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.Proc Natl Acad Sci U S A. 2008; 105: 16731-16736
- Specificities of the fecal microbiota in inflammatory bowel disease.Inflamm Bowel Dis. 2006; 12: 106-111
- Decreased diversity of the fecal micriobiome in recurrent clostridium difficile-associated diarrhea.J Infect Dis. 2008; 197: 435-438
- Changes in the composition fo the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea.J Clin Gastroenterol. 2010; 44: 354-360
- Duodenal infusion of the donor feces for recurrent clostridium difficile.N Engl J Med. 2013; 368: 407-415
Midthun K. FDA Letter to the American Gastroenterological Association. Available at: http://highroadsolution.com/file_upload_2/files/fda+response+letter+to+fmt+inquiry.pdf. Accessed March 18, 2014.
U.S. Food and Drug Administration. Important information about IND requirments for use of fecal micobiota to treat clostridium difficile infection not responsive to standard therapies. Available at: http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm357258.htm. Accessed March 18, 2014.
Hamblin J. Fecal transplantation: ‘we have an effective treatment, but its too gross'. The Atlantic. 2013. Available at: http://www.theatlantic.com/health/print/2013/01/fecal-transplantation-we-have-an-effective-treatment-but-its-is-too-gross/267389/. Accessed June 4, 2013.
Conflicts of Interest: MM is on the speakers bureau for Optimer Pharmaceuticals (Dificid). The other authors have no potential conflicts of interest to report.
Authorship: All authors had access to all data and editions of the manuscript as well as contributing to the ideas, planning, and writing of this article.
ScienceDirectAccess this article on ScienceDirect
- Fecal Microbiota Transplantation: The Case of Immunocompromised PatientsThe American Journal of MedicineVol. 128Issue 3
- PreviewI read with great interest the review by Austin et al about fecal microbiota transplantation in the treatment of Clostridium difficile infections.1 They rightly point out that fecal microbiota transplantation is efficacious for patients with recurrent C. difficile infection, with an excellent short-term safety profile. However, I want to raise a safety concern for comment, that is, the case of immunocompromised patients not evoked by the authors.